Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin for endothelial glycocalyx protection during liver transplantation
ChiCTR1800016776Phase 4Recruiting
- Sponsor
- Beijing Chaoyang Hospital, Capital Medical University
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of ulinastatin in Vascular endothelial glycocalyx injury (EGI) (4 arms), sponsored by Beijing Chaoyang Hospital, Capital Medical University. Primary endpoints: Syndecan-1, serum albumin and 1 more. Started Jun 2018; status: recruiting.
02
Drugs
ulinastatin
03
Conditions
Vascular endothelial glycocalyx injury (EGI)
Beyond the preview
Go deeper on ChiCTR1800016776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016776.